Hims & Hers Health (HIMS) Projected to Post Earnings on Monday

Hims & Hers Health (NYSE:HIMS) is projected to post its Q4 2025 results after the market closes on Monday, February 23rd. Analysts expect the company to announce earnings of $0.04 per share and revenue of $619.4790 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, February 23, 2026 at 5:00 PM ET.

Hims & Hers Health Stock Down 1.2%

HIMS stock opened at $15.62 on Friday. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The firm has a market capitalization of $3.56 billion, a P/E ratio of 28.93, a P/E/G ratio of 2.92 and a beta of 2.43. Hims & Hers Health has a 52-week low of $15.29 and a 52-week high of $70.43. The company’s 50 day simple moving average is $28.63 and its 200-day simple moving average is $40.35.

Hims & Hers Health announced that its Board of Directors has approved a share buyback program on Monday, November 17th that allows the company to buyback $250.00 million in shares. This buyback authorization allows the company to purchase up to 3% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. UBS Group set a $32.00 target price on Hims & Hers Health in a report on Tuesday, November 4th. Barclays initiated coverage on shares of Hims & Hers Health in a research report on Monday, December 8th. They issued an “overweight” rating and a $48.00 target price for the company. Leerink Partners upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. Finally, Citigroup reduced their price objective on Hims & Hers Health from $30.00 to $16.50 and set a “sell” rating for the company in a research report on Monday, February 9th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $39.32.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Acquisition expands international footprint and revenue run‑rate — Hims & Hers agreed to buy Australian digital‑health provider Eucalyptus in a deal worth up to $1.15 billion, a move management says will accelerate global growth and add a high‑growth revenue stream. Hims & Hers Health to acquire Australia’s Eucalyptus for up to $1.15 billion
• Positive Sentiment: Deal expected to materially increase top line and international scale — Coverage notes Eucalyptus brings ~ $450M of annual revenue growing at triple‑digit rates and should accelerate HIMS’ personalized care footprint outside the U.S. Hims & Hers HUGE Acquisition News!
• Positive Sentiment: Product/technology expansion — Hims is ramping AI‑driven preventive care (menopause, low testosterone, multi‑cancer testing and deeper personalization), which supports a higher‑value platform positioning longer term. Hims & Hers Accelerates AI Preventive Care and Platform Strategy
• Neutral Sentiment: Analysts flag mixed near‑term earnings implications — Some previews say platform strength and new specialties could help Q4 results, but recognize higher costs tied to deals and expansion may cloud near‑term profitability. Can Platform Strength Support Hims & Hers Stock Before Q4 Earnings?
• Negative Sentiment: Regulatory and legal scrutiny around GLP‑1/weight‑loss products — Coverage reports the company’s earlier GLP‑1/compounder strategy drew backlash from drugmakers and regulators, raising compliance, litigation and reputational risks that could hurt sales and margins. Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders
• Negative Sentiment: Reputational headlines and legal risk over “copycat” weight‑loss drugs — Media coverage and analysis highlight mounting criticism that could pressure demand or invite enforcement actions. Hims & Hers under fire over copycat weight loss drugs
• Neutral Sentiment: Deal financing and integration risk — Commentators note HIMS will use significant cash (and potentially other consideration) for the deal, raising questions about near‑term balance sheet flexibility and execution risk on integrating Eucalyptus. Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills?

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 23,090 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $35.72, for a total value of $824,774.80. Following the completion of the sale, the chief financial officer owned 94,333 shares of the company’s stock, valued at $3,369,574.76. The trade was a 19.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Patrick Harrison Carroll sold 10,021 shares of the company’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $367,870.91. Following the sale, the insider owned 169,940 shares of the company’s stock, valued at approximately $6,238,497.40. This trade represents a 5.57% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 82,963 shares of company stock valued at $2,944,621. Insiders own 13.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors have recently modified their holdings of the company. SkyView Investment Advisors LLC acquired a new position in shares of Hims & Hers Health during the second quarter valued at about $226,000. Palisade Capital Management LP bought a new position in Hims & Hers Health during the second quarter valued at about $224,000. Kovack Advisors Inc. bought a new position in Hims & Hers Health during the fourth quarter valued at about $216,000. Marshall Wace LLP acquired a new position in Hims & Hers Health in the 4th quarter valued at approximately $204,000. Finally, Northwestern Mutual Wealth Management Co. lifted its position in shares of Hims & Hers Health by 490.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,140 shares of the company’s stock worth $102,000 after acquiring an additional 2,608 shares during the period. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.